Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
6,55 EUR | +0,77 % |
|
+5,65 % | -14,94 % |
Kurzporträt
Mitarbeiterzahl: 1 838
Umsatz nach Geschäftsbereich
JPY in Millionen | 2023 | Gewichtung | 2024 | Gewichtung | Delta |
---|---|---|---|---|---|
Reagent
73,5
%
| 65 925 | 84,4 % | 31 961 | 73,5 % | -51,52 % |
Brokerage
18,4
%
| 8 200 | 10,5 % | 7 997 | 18,4 % | -2,48 % |
Genetic Medicine
6,1
%
| 2 640 | 3,4 % | 2 653 | 6,1 % | +0,49 % |
Equipment
2,1
%
| 1 375 | 1,8 % | 892 | 2,1 % | -35,13 % |
Umsatz je Region
JPY in Millionen | 2023 | Gewichtung | 2024 | Gewichtung | Delta |
---|---|---|---|---|---|
Japan
35,5
%
| 45 667 | 58,4 % | 15 434 | 35,5 % | -66,20 % |
United States
29,8
%
| 12 886 | 16,5 % | 12 974 | 29,8 % | +0,68 % |
China
16,2
%
| 10 799 | 13,8 % | 7 039 | 16,2 % | -34,82 % |
Europe
10,3
%
| 4 949 | 6,3 % | 4 496 | 10,3 % | -9,15 % |
Asia excluding Japan and China
7,7
%
| 3 546 | 4,5 % | 3 355 | 7,7 % | -5,39 % |
Others
0,5
%
| 293 | 0,4 % | 205 | 0,5 % | -30,03 % |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Director of Finance/CFO | 68 | 01.06.14 | |
Koichi Nakao
PSD | President | 62 | 01.04.02 |
Takuya Kakemi
ADM | Chief Administrative Officer | - | - |
Junichi Mineno
COO | Chief Operating Officer | 63 | 01.04.04 |
Director/Board Member | 60 | 01.01.09 | |
Masanobu Kimura
BRD | Director/Board Member | 60 | 01.05.13 |
Human Resources Officer | - | - | |
Akihiko Kita
AUD | Comptroller/Controller/Auditor | 64 | 01.04.05 |
Corporate Officer/Principal | - | - | |
Masahide Tamaki
AUD | Comptroller/Controller/Auditor | 64 | 01.04.05 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Hisashi Omiya
CHM | Chairman | 81 | 01.04.02 |
Masanobu Kimura
BRD | Director/Board Member | 60 | 01.05.13 |
Koichi Nakao
PSD | President | 62 | 01.04.02 |
Director of Finance/CFO | 68 | 01.06.14 | |
Director/Board Member | 60 | 01.01.09 | |
Junichi Mineno
COO | Chief Operating Officer | 63 | 01.04.04 |
Kazuko Kimura
BRD | Director/Board Member | 73 | 01.06.19 |
Nobuko Kawashima
BRD | Director/Board Member | 61 | 01.06.16 |
Director/Board Member | 53 | 01.06.20 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 0 | 120 415 600 | 47 065 600 ( 39,09 %) | 0 | 39,09 % |
Unternehmenskontakt
![Straße Takara Bio Inc.(TF2)](https://cdn.zonebourse.com/static/address/465104.png)
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Cellectis AB
![]() Cellectis AB BiotechnologyHealth Technology Part of Takara Holdings, Inc., Cellectis AB is a Swedish company that manufactures and distributes stem cell-related products. The company is based in Gothenburg, Sweden. Cellectis was acquired by Takara Bio, Inc. from Cellectis SA on September 04, 2014. |
Biotechnology
|
Takara Bio Europe SAS
![]() Takara Bio Europe SAS Medical SpecialtiesHealth Technology Takara BIO Europe SAS provides kits, reagents, instruments, and services that enable life sciences researchers to achieve their experimental objectives. It offers automation systems, stem cell research, real time PCR, nucleic acid purification, cloning, cell biology assays, gene function, antibodies, and ELISAs. The company is headquartered in Saint-Germain-en-Laye, France. |
Medical Specialties
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
![Analystenschätzungen](/images/consensus_flch.gif)
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+24,74 % | 47,96 Mrd. | |
-0,47 % | 42,45 Mrd. | |
+43,96 % | 41,47 Mrd. | |
+25,40 % | 31,6 Mrd. | |
+17,96 % | 28,63 Mrd. | |
-4,47 % | 28,03 Mrd. | |
+50,73 % | 14,56 Mrd. | |
+42,56 % | 14,14 Mrd. | |
+1,46 % | 12,58 Mrd. |
- Börse
- Aktien
- A0DNGL Aktie
- A0DNGL Aktie
- Unternehmen Takara Bio Inc.